Announcements

FNIH Biomarkers Consortium Launches ChIIME to Identify Biomarkers that Predict Response to Immunotherapy in Breast Cancer Patients

October 21, 2019 — The Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium has launched a new project under its Cancer Steering Committee that will identify biological markers (biomarkers) that predict personalized response to immunotherapy after a patient receives chemotherapy. The “Chemotherapeutic Impact on the Immune MicroEnvironment (ChIIME)” project will use a cutting-edge technology called single nucleus RNA sequencing to analyze metastatic breast cancer samples.

Read More

FNIH Biomarkers Consortium Launches Project that will Standardize the Measurement of Genetic Blood Tests to Track Cancer

September 24, 2019 — The Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium has launched a new project under its Cancer Steering Committee that will standardize the assessment of genetic tests that use blood samples to track cancer in hospitals and laboratories across the United States. In particular, the project will develop tools to enable clinicians to measure and confidently compare circulating tumor DNA (ctDNA) test results across different laboratories.

Read More

FNIH President Dr. Maria Freire Wins NonProfit PRO's "Executive of the Year" Award

BETHESDA, MD, June 13, 2019 — The Foundation for the National Institutes of Health (FNIH) is proud to announce that President and Executive Director Maria C. Freire, Ph.D., has been named “Executive of the Year” by NonProfit PRO.

Read More

FNIH Biomarkers Consortium Launches NIMBLE to Replace Invasive and Painful Biopsy with Non-Invasive Biomarkers for Liver Disease

June 11, 2019 – The FNIH Biomarkers Consortium has launched a new project under its Metabolic Disorders Steering Committee that will standardize biological markers (biomarkers) that help diagnose Non-Alcoholic SteatoHepatitis (NASH) – a type of liver disease. The “Non-Invasive Biomarkers of Metabolic Liver DiseasE (NIMBLE)” project will directly compare imaging and blood-based biomarkers to biopsy results to define the best tools for diagnosing NASH.

Read More

The FNIH Earns Highest Rating From Charity Navigator for the Fifth Consecutive Year

April 23, 2019 - The Foundation for the National Institutes of Health (FNIH) has received top honors again this year from Charity Navigator by earning it’s coveted 4-star rating. Charity Navigator, the nation’s largest independent charity evaluator, has recognized the FNIH with its highest rating for demonstrating strong financial health and commitment to accountability and transparency.

Read More

Remembering Andrew Lee

April 22, 2019 - The Board and staff of the FNIH mourn the passing of our beloved friend Andrew Lee, who died on April 21, 2019 at the age of 23. In 2018, the FNIH bestowed the Charles A. Sanders, M.D., Partnership Award to Andrew for his unwavering commitment to advancing biomedical research for rare kidney cancers.

Read More

FNIH Launches New Project to Improve Vaccination Against Tuberculosis

March 19, 2019 — The Foundation for the National Institutes of Health (FNIH) has launched a new project that will develop better vaccines to prevent tuberculosis (TB). Through the new project, titled “Understanding the mechanisms of intravenous BCG-induced protection against TB in NHP,” researchers will analyze the effects of delivering the only current TB vaccine, Bacillus Calmette Guerin (BCG), through a new route, intravenously (IV), in an attempt to better prevent TB.

Read More

Q&A With David Fryburg, M.D., Principal Consultant, ROI BioPharma Consulting: Building Tools to Improve Diabetes Drug Development

January 25, 2019  Since 2011, the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium has been shedding new light on diabetes – a disease that affects more than 30 million people in the United States – by examining the function of the beta cell. Found within the pancreas, the beta cell has the critical role of producing and secreting insulin – an essential hormone necessary for the control of blood sugar and metabolism. In patients with diabetes, the beta cell is attacked or destroyed by the immune system (Type 1 diabetes) or is unable to produce enough insulin to control blood sugar levels (Type 2 diabetes). 

Read More

Accelerating Medicines Partnership (AMP) Extends the RA and Lupus Research Program to Maximize the Benefits of Emerging Technologies to Advance New Therapies

December 14, 2018  The Foundation for the National Institutes of Health (FNIH) announces that the Accelerating Medicines Partnership (AMP) is extending the Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE) & Related Autoimmune Disorders program to a sixth year. 

Read More

FNIH Statement on the Moderate Alcohol and Cardiovascular Health Trial Follow-Up Report

December 13, 2018  Today, the National Institutes of Health (NIH) Advisory Committee to the Director (ACD) issued a follow-up report on the Moderate Alcohol and Cardiovascular Health Trial (MACH). The following is the FNIH’s statement on the report. 

Read More